Hypothesis

We propose that the NAD+ transporter SLC25A51 (also known as the mitochondrial NAD+ carrier) couples compartment‑specific NAD+ biosynthesis to the assembly of respiratory supercomplexes by modulating the redox state of newly synthesized Complex I subunits. Increased nuclear NAD+ sustains PARP‑1 activity, which PARylates PGC‑1α at lysine residues, enhancing its transcriptional co‑activator function. Simultaneously, elevated mitochondrial NAD+ through SLC25A51 import promotes NAD+-dependent deacetylation of newly imported Complex I NDUFA9 subunits by SIRT3, favoring their incorporation into I+III2+IV supercomplexes. Disruption of this NAD+ shuttling uncouples biogenesis from supercomplex formation, leading to excess ROS despite increased mitochondrial mass.

Rationale

• PGC‑1α activation restores TFAM‑mediated biogenesis and membrane potential, yet ROS reduction depends on proper electron flow through assembled supercomplexes (see 1 and 5).
• TBK1 inhibition independently raises mitochondrial mass, indicating that biogenesis can be stimulated without addressing ETC organization (2).
• Compartmentalized NAD+ biosynthesis dictates nuclear versus cytosolic pools, with high glucose shunting NMN to cytosolic NMNAT‑2 and depriving nuclear NAD+ for PARP‑1 (3). The physiological role of mitochondrial NMNAT‑3 and real‑time NAD+/NADH flux remains undefined (4).
• SLC25A51 imports cytosolic NAD+ into the matrix, linking cytosolic NAD+ synthesis to mitochondrial redox reactions; its activity is modulated by the NAD+/NADH ratio and membrane potential.

We hypothesize that SLC25A51 activity is the rate‑limiting step that translates NAD+ compartmentalization into efficient supercomplex assembly, thereby determining whether increased mitochondrial biogenesis translates into improved oxidative phosphorylation.

Testable Predictions

1. Increased SLC25A51 expression will raise mitochondrial NAD+ levels, enhance SIRT3‑mediated deacetylation of Complex I subunits, and promote I+III2+IV supercomplex formation without altering total mitochondrial mass.
2. Pharmacological inhibition or siRNA knock‑down of SLC25A51 will blunt supercomplex assembly despite elevated PGC‑1α‑driven biogenesis, resulting in higher ROS production and reduced ATP output.
3. PARP‑1 activation (via low‑dose DNA damage or NAD+ precursors) will increase PARylation of PGC‑1α, amplifying its transcriptional activity on SLC25A51 and other mitochondrial genes, creating a feed‑forward loop that couples nuclear NAD+ status to mitochondrial NAD+ import.
4. High glucose conditions will decrease SLC25A51‑mediated NAD+ import due to cytosolic NMNAT‑2 sequestration of NMN, leading to reduced supercomplex assembly and increased ROS, which can be rescued by overexpressing SLC25A51 or providing membrane‑permeable NAD+ analogs.

Experimental Design

• Cell models: Use HEK293T and primary neuronal cultures transfected with SLC25A51 overexpression or CRISPRi constructs; treat with ZLN005 (to activate PGC‑1α) or TBK1 inhibitor (as in 2).
• Readouts:
  • Measure compartment‑specific NAD+/NADH using Peredox‑mito and SoNar biosensors.
  • Quantify supercomplex abundance by BN‑PAGE followed by immunoblotting for Complex I, III, and IV.
  • Assess SIRT3 activity via acetylation status of NDUFA9 (immunoprecipitation‑Western).
  • Determine ROS (MitoSOX) and ATP production (luciferase assay).
  • Monitor PARP‑1 activity and PGC‑1α PARylation (anti‑PAR immunoblot).
• Conditions: Normal glucose (5 mM) vs. high glucose (25 mM); +/- NAD+ precursor (NR or NMN); +/- PARP‑1 inhibitor (Olaparib).
• Controls: Empty vector, non‑targeting siRNA, and mitochondria‑targeted catalase to isolate ROS sources.

Potential Outcomes and Falsifiability

• Supporting outcome: SLC25A51 overexpression rescues supercomplex formation and lowers ROS in high‑glucose or SLC25A51‑knockdown cells, even when PGC‑1α is hyperactive. Inhibition of SLC25A51 abolishes the benefit of ZLN005 on ATP yield despite increased mitochondrial mass.
• Falsifying outcome: Manipulating SLC25A51 levels does not affect supercomplex assembly, ROS, or ATP under any condition, indicating that NAD+ transport is not rate‑limiting for ETC organization.
• Alternative outcome: Changes in supercomplex assembly correlate solely with alterations in mitochondrial NAD+ consumption (e.g., via complex I activity) rather than import, suggesting that matrix NAD+ utilization, not transport, drives the process.

By directly linking NAD+ compartmentalization to the structural organization of the electron transport chain, this hypothesis moves beyond generic NAD+ supplementation and offers a precise, testable mechanism for optimizing mitochondrial function in metabolic and neurodegenerative contexts.